Hulks G, Patel K R
Department of Respiratory Medicine, Western Infirmary, Glasgow, UK.
Pulm Pharmacol. 1989;2(3):161-2. doi: 10.1016/0952-0600(89)90041-0.
We have studied the effect of inhaled ouabain on resting bronchomotor tone and histamine responsiveness in eight asthmatic patients in an attempt to clarify the role of Na/K ATPase in airway reactivity. Doses ranged from 50 micrograms to 5000 micrograms and were given in a placebo controlled, double blind manner. Baseline FEV1 was recorded prior to inhalation and at intervals up to 30 min thereafter. At 30 min, a histamine provocation test was performed and results expressed as that concentration producing a 20% fall in FEV1. Maximum fall in FEV1 was not significantly different between placebo or any dose of ouabain, ranging from 4.3%-8.2% (p greater than 0.06) nor was histamine reactivity altered significantly (geometric mean range 0.17 mg-0.29 mg [p greater than 0.2]). Unlike animal studies therefore, we have been unable to demonstrate any effect of Na/K ATPase inhibition on airway reactivity in vivo.
我们研究了吸入哇巴因对8名哮喘患者静息支气管运动张力和组胺反应性的影响，以阐明钠钾ATP酶在气道反应性中的作用。剂量范围为50微克至5000微克，采用安慰剂对照、双盲方式给药。在吸入前及之后长达30分钟的间隔时间记录基础第一秒用力呼气容积（FEV1）。在30分钟时，进行组胺激发试验，结果以导致FEV1下降20%的浓度表示。安慰剂或任何剂量的哇巴因组FEV1的最大下降幅度无显著差异，范围为4.3%-8.2%（p>0.06），组胺反应性也未显著改变（几何平均范围为0.17毫克-0.29毫克[p>0.2]）。因此，与动物研究不同，我们未能证明体内抑制钠钾ATP酶对气道反应性有任何影响。
